Experimental Autoimmune Encephalomyelitis is Associated with Changes of the Microbiota Composition in the Gastrointestinal Tract
收藏NIAID Data Ecosystem2026-03-12 收录
下载链接:
https://www.ncbi.nlm.nih.gov/sra/SRP268533
下载链接
链接失效反馈官方服务:
资源简介:
The gut microbiome is known to be sensitive to changes in the immune system, especially during autoimmune diseases such as Multiple Sclerosis (MS). Our study examines the changes to the gut microbiome that occur during Experimental Autoimmune Encephalomyelitis (EAE), an animal model for MS. We collected fecal samples at key stages of EAE progression and quantified microbial abundances with 16S V4 amplicon sequencing. Our analysis of the data suggests that commensal Lactobacillaceae fall in abundance during EAE while other commensal populations belonging to the Clostridiaceae, Ruminococcaceae, and Peptostreptococcaceae families expand. Community analysis with microbial co-occurrence networks points to these three taxa as mediators of gut microbiome dysbiosis. We also employed PICRUSt2 to impute MetaCyc Enzyme Consortium (EC) pathway abundances from the original microbial abundance data. From this analysis, we found that a number of imputed EC pathways responsible for the production of compounds with indole groups are enriched in mice undergoing EAE. Our analysis and interpretation of results provides a detailed picture of the changes to the gut microbiome that are occurring throughout the course of EAE disease progression. Overall design: Three-group experimental autoimmune encephalomyelitis (EAE) study in which one group was left naïve, one was immnuized with Complete Freund's Adjuvant (CFA), and one was immunized with an emulsion of MOG (myelin oligodendrocyte protein) and CFA to induce EAE. Fecal samples were taken at 2 days before immunizations and at 8, 14, 19, and 29 days afterwards during the progression of EAE. Fecal samples were processed for 16S amplicon sequencing to identify and quantify microbes and their abundances over time and accross immunization treatments. Sequencing performed at UVa Genome Analysis & Technology Core, Office of Research Core Administration. University of Virginia Health System, P.O. Box 800741, Charlottesville, VA 22908-0741
创建时间:
2020-10-03



